A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Clinical trial NCT05433480 · UNKNOWN
Trial details
- NCT number
- NCT05433480
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-25
- Primary completion
- 2023-12-31
- Enrollment
- 274
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.